What Could a New Drug Approval Mean for CLL Patients?

Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Dr. Wierda reviews the treatment’s indications, the potential side effects and shares his perspective on what the approval could mean for a broader group of patients in the future.

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo